Mark Elliott Boulding Sells 2,276 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCTGet Rating) VP Mark Elliott Boulding sold 2,276 shares of the firm’s stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $45.17, for a total transaction of $102,806.92. Following the transaction, the vice president now directly owns 61,110 shares of the company’s stock, valued at $2,760,338.70. The sale was disclosed in a document filed with the SEC, which is available through this link.

Mark Elliott Boulding also recently made the following trade(s):

  • On Tuesday, April 5th, Mark Elliott Boulding sold 5 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.00, for a total transaction of $225.00.
  • On Thursday, February 10th, Mark Elliott Boulding sold 17,935 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.03, for a total transaction of $807,613.05.
  • On Tuesday, February 1st, Mark Elliott Boulding sold 779 shares of PTC Therapeutics stock. The stock was sold at an average price of $40.00, for a total transaction of $31,160.00.

NASDAQ:PTCT opened at $44.50 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.84 and a debt-to-equity ratio of 679.17. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -5.99 and a beta of 0.89. The firm’s fifty day simple moving average is $38.67 and its 200 day simple moving average is $38.85. PTC Therapeutics, Inc. has a twelve month low of $32.44 and a twelve month high of $50.26.

PTC Therapeutics (NASDAQ:PTCTGet Rating) last posted its earnings results on Tuesday, February 22nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.24). The business had revenue of $165.20 million for the quarter, compared to analyst estimates of $161.08 million. PTC Therapeutics had a negative net margin of 97.27% and a negative return on equity of 351.90%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.08) EPS. On average, analysts predict that PTC Therapeutics, Inc. will post -5.26 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in PTCT. Fisher Asset Management LLC increased its stake in PTC Therapeutics by 9.8% during the 3rd quarter. Fisher Asset Management LLC now owns 176,156 shares of the biopharmaceutical company’s stock worth $6,555,000 after buying an additional 15,671 shares during the period. State of New Jersey Common Pension Fund D increased its stake in PTC Therapeutics by 9.4% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 71,138 shares of the biopharmaceutical company’s stock worth $2,647,000 after buying an additional 6,136 shares during the period. Tygh Capital Management Inc. increased its stake in PTC Therapeutics by 21.4% during the 3rd quarter. Tygh Capital Management Inc. now owns 46,472 shares of the biopharmaceutical company’s stock worth $1,729,000 after buying an additional 8,189 shares during the period. Raymond James & Associates increased its stake in PTC Therapeutics by 4.6% during the 3rd quarter. Raymond James & Associates now owns 7,125 shares of the biopharmaceutical company’s stock worth $265,000 after buying an additional 311 shares during the period. Finally, Asymmetry Capital Management L.P. purchased a new stake in PTC Therapeutics during the 3rd quarter worth $8,037,000.

PTCT has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on shares of PTC Therapeutics from $70.00 to $76.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 23rd. Barclays dropped their price objective on shares of PTC Therapeutics from $40.00 to $39.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 23rd. StockNews.com assumed coverage on shares of PTC Therapeutics in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $63.00 target price (down previously from $64.00) on shares of PTC Therapeutics in a research report on Friday, April 1st. Finally, Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “sell” rating in a research report on Wednesday, January 26th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $51.70.

PTC Therapeutics Company Profile (Get Rating)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.

Featured Articles

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.